Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been continuously funded by the National Cancer Institute, American Cancer Society (ACS), Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), Susan G. Komen and Breast Cancer Research foundations, Cancer Prevention Research Institute of Texas, and industry.
Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, Cella D, Meropol NJ, Alpaugh RK, Saphner TJ, Swaney RE, Hoelzer KL, Gradishar WJ, Abramson VG, Sundaram PK, Jilani SZ, Perez EA, Lin NU, Jahanzeb M, Wolff AC, Sledge GW, Reid SA, Breast Cancer Res Treat 2024 Jul
— 2024cited by 0position: selected
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K, J Clin Invest 2024 Feb
— 2024cited by 0position: selected
Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Abstract PD1-03: A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in <i>FGFR</i>-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer